Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,491–1,500 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1491
- Medicine slug
- teriparatide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab322675-4769-45b0-b146-14fbaa3135d0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of Teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d371f0f7-d492-4481-b360-051456d56d65 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38b470a-2e62-487b-b3e7-134d3d1958b5 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d3f65e2-e8f0-4d33-b79e-989013dd3ca3 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae667c5-381f-4f92-93df-2ed6158d07b0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d77d40db-7f38-88eb-fd5d-4282f0642028 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
The half-life of teriparatide in serum was approximately 1 hour when administered by subcutaneous injection.
Projected row 1492
- Medicine slug
- teriparatide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
0.12 L/kg
- Numeric value
- 0.12
- Unit
- L/kg
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d0c89a2-3849-adf6-007d-aeca21cf417c (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b007339-dd0d-f019-5e0a-9b1b0f75011c (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab322675-4769-45b0-b146-14fbaa3135d0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d371f0f7-d492-4481-b360-051456d56d65 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution - Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38b470a-2e62-487b-b3e7-134d3d1958b5 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d3f65e2-e8f0-4d33-b79e-989013dd3ca3 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aae667c5-381f-4f92-93df-2ed6158d07b0 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d77d40db-7f38-88eb-fd5d-4282f0642028 (opens source in a new tab)
Teriparatide label
Version not recorded · Effective date not recorded
Distribution — Volume of distribution following intravenous injection is approximately 0.12 L/kg.
Projected row 1493
- Medicine slug
- tesamorelin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
0.15 h
- Numeric value
- 0.15
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d783378-b02d-4f19-99dd-0fc91a042224 (opens source in a new tab)
Tesamorelin label
Version not recorded · Effective date not recorded
The median peak plasma tesamorelin concentration (T max ) was 0.15 h in both populations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:839334d3-8c1d-4c26-9036-2ab524a6ea75 (opens source in a new tab)
Tesamorelin label
Version not recorded · Effective date not recorded
The median peak plasma tesamorelin concentration (T max ) was 0.15 h in both populations.
Projected row 1494
- Medicine slug
- tetrabenazine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
17.5 hours
- Numeric value
- 17.5
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49587379-1cc0-48ff-9f2f-517079cf499d (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef5f9dd4-945f-ec27-518d-90996a7bd4b6 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:471ac1d8-e3ad-7729-87c5-c26ae92c32eb (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6775241b-9703-4876-88fd-bbeb906f789d (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03c3cf8-fcd4-4dbf-a4f5-59bd7887c902 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7d93006-7f06-4da4-985e-6b948c2468e8 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aca55884-1eb4-4a76-8c7f-96c782849337 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acf78d97-fca5-49aa-8683-6db7396da72f (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5867189c-17bd-4e70-a079-c4730f9950d1 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5042f30c-c922-4835-bf6d-40905f2dc76c (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac768bab-8afa-4446-bc7f-caeeffec0cda (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbfb791e-26ac-9fb5-e053-2995a90ac7e5 (opens source in a new tab)
Tetrabenazine label
Version not recorded · Effective date not recorded
The elimination half-life of tetrabenazine in subjects with hepatic impairment was approximately 17.5 hours.
Projected row 1495
- Medicine slug
- tetrakis-copper-tetrafluoroborate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49662def-2fb9-47b2-8467-ca56f6006167 (opens source in a new tab)
Tetrakis Copper Tetrafluoroborate label
Version not recorded · Effective date not recorded
The effective half-life of clearance (which includes both the biological half-life and radionuclide decay) for the heart is approximately 3 hours, and for the liver is approximately 30 minutes, after a rest or exercise injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c03a854-185a-45d7-883f-9f87e4750181 (opens source in a new tab)
Tetrakis Copper Tetrafluoroborate label
Version not recorded · Effective date not recorded
The effective half-life of clearance (which includes both the biological half-life and radionuclide decay) for the heart is approximately 3 hours, and for the liver is approximately 30 minutes, after a rest or exercise injection.
Projected row 1496
- Medicine slug
- theophylline
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
98.8%
- Numeric value
- 98.8
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa80b9f4-8a5d-3e14-e053-2a95a90a8aab (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Steady-state results were: 600 MG TABLET FED 600 MG (ONE + ONE-HALF 400 MG TABLETS) FED AUC 0-24 hrs (mcg hr/mL) 209.77 ± 51.04 212.32 ± 56.29 C max (mcg/mL) 12.91 ± 2.46 13.17 ± 3.11 C min (mcg/mL) 5.52 ± 1.79 5.39 ± 1.95 T max (hours) 8.62 ± 3.21 7.23 ± 2.35 Percent Fluctuation 183.73 ± 54.02 179.72 ± 28.86 The bioavailability ratio for the 600/400 mg tablets was 98.8%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f1d1da-ce61-45b3-acf4-903cc81d16da (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Steady-state results were: 600 MG TABLET FED 600 MG (ONE + ONE-HALF 400 MG TABLETS) FED AUC 0-24 hrs (mcg hr/mL) 209.77±51.04 212.32±56.29 C max (mcg/mL) 12.91±2.46 13.17±3.11 C min (mcg/mL) 5.52±1.79 5.39±1.95 T max (hours) 8.62±3.21 7.23±2.35 Percent Fluctuation 183.73±54.02 179.72±28.86 The bioavailability ratio for the 600/400 mg tablets was 98.8%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fc2167-ceb6-4e3e-8ff7-5e400dfbd533 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Steady-state results were: 600 mg Tablet FED 600 mg (One + One-Half 400 mg Tablets) FED AUC 0-24 hrs (mcg/mL) 209.77 ± 51.04 212.32 ± 56.29 C max (mcg/mL) 12.91 ± 2.46 13.17 ± 3.11 C min (mcg/mL) 5.52 ± 1.79 5.39 ± 1.95 T max (hours) 8.62 ± 3.21 7.23 ± 2.35 Percent Fluctuation 183.73 ± 54.02 179.72 ± 28.86 The bioavailability ratio for the 600/400 mg tablets was 98.8%.
Projected row 1497
- Medicine slug
- theophylline
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 0.607143
- Recorded readings
8.3 hours
- Numeric value
- 8.3
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63517422-45a0-4e78-8505-eca054068ee9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf320619-c53b-49a7-97b5-cd0c075a9f75 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48330a8e-be08-4d38-b8b1-d30fbd5a35de (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6ca5cc9-4e5e-40cf-a36e-227aa4cb55c6 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0d5d1cd-c79b-4229-929c-2eb3e4f43298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abdfb9b9-9402-4761-9347-8eb1c4d86242 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31f3c720-1597-4d43-9296-33017b90b15f (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2-12.2) and mean clearance of 3.5 L/hour (range 2.3-5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:098db8bb-fa9a-4577-b7d9-86caaefc168a (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2-12.2) and mean clearance of 3.5 L/hour (range 2.3-5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77e849b8-900b-4f0d-ac5c-1391abcd5721 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2-12.2) and mean clearance of 3.5 L/hour (range 2.3-5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9591d4db-2b88-4f0f-b61e-64ba67626e3d (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a422c32-bbdf-4297-84f4-9c438c904b0c (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac490ebf-24e1-47c4-a932-ad4dcafe7aad (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2-12.2) and mean clearance of 3.5 L/hour (range 2.3-5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f93e20b1-97aa-088d-e053-6394a90a25d4 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a90ccf-9c32-40cc-9008-7e55b3da4dfd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eabefa-518b-4030-9b72-01ac8b3deba9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e64036a-ee3e-42e7-9e59-881f88a4e298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:701fbf9c-e06b-46f4-863b-981acf3021aa (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The subjects used for this study exhibited a mean half-life of 8.3 hours (range 5.2 to 12.2) and mean clearance of 3.5 L/hour (range 2.3 to 5.6) as determined in a separate single-dose clearance study using 500 mg of immediate-release theophylline, prior to this multiple-dose study.
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62fb84a9-4e75-4f4b-8f15-1fd1bb7ae4dd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2716dac-8b23-4e06-bc3e-4dd76b7c813e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa80b9f4-8a5d-3e14-e053-2a95a90a8aab (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47e484c2-f59e-4a71-bb97-c90f128ac345 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f1d1da-ce61-45b3-acf4-903cc81d16da (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b685384-5d96-46fa-b93b-e96538a2cfe7 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:955dba5e-c3b7-4a45-8650-e1b4722dbaea (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b9780f-c46f-4e0f-9641-2cab60600e6e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fc2167-ceb6-4e3e-8ff7-5e400dfbd533 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78a99bfe-6ebe-4ace-80b0-ee019921435e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a108fa0-c230-475f-be93-6f864b98a410 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
Projected row 1498
- Medicine slug
- theophylline
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 0.607143
- Recorded readings
8.31 hours
- Numeric value
- 8.31
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63517422-45a0-4e78-8505-eca054068ee9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf320619-c53b-49a7-97b5-cd0c075a9f75 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48330a8e-be08-4d38-b8b1-d30fbd5a35de (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6ca5cc9-4e5e-40cf-a36e-227aa4cb55c6 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0d5d1cd-c79b-4229-929c-2eb3e4f43298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abdfb9b9-9402-4761-9347-8eb1c4d86242 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31f3c720-1597-4d43-9296-33017b90b15f (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:098db8bb-fa9a-4577-b7d9-86caaefc168a (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77e849b8-900b-4f0d-ac5c-1391abcd5721 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9591d4db-2b88-4f0f-b61e-64ba67626e3d (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a422c32-bbdf-4297-84f4-9c438c904b0c (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac490ebf-24e1-47c4-a932-ad4dcafe7aad (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f93e20b1-97aa-088d-e053-6394a90a25d4 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a90ccf-9c32-40cc-9008-7e55b3da4dfd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eabefa-518b-4030-9b72-01ac8b3deba9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e64036a-ee3e-42e7-9e59-881f88a4e298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:701fbf9c-e06b-46f4-863b-981acf3021aa (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
Mean peak theophylline serum levels (C max ) was 6.69 mcg/mL and mean time of peak serum concentration (T max ) was 8.31 hours.
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62fb84a9-4e75-4f4b-8f15-1fd1bb7ae4dd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2716dac-8b23-4e06-bc3e-4dd76b7c813e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa80b9f4-8a5d-3e14-e053-2a95a90a8aab (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47e484c2-f59e-4a71-bb97-c90f128ac345 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f1d1da-ce61-45b3-acf4-903cc81d16da (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b685384-5d96-46fa-b93b-e96538a2cfe7 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:955dba5e-c3b7-4a45-8650-e1b4722dbaea (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b9780f-c46f-4e0f-9641-2cab60600e6e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fc2167-ceb6-4e3e-8ff7-5e400dfbd533 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady-state, on a dosage regimen with 24-hour intervals, the expected mean trough concentration is approximately 50% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78a99bfe-6ebe-4ace-80b0-ee019921435e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a108fa0-c230-475f-be93-6f864b98a410 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours.
Projected row 1499
- Medicine slug
- theophylline
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
0.45 L/kg
- Numeric value
- 0.45
- Unit
- L/kg
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62fb84a9-4e75-4f4b-8f15-1fd1bb7ae4dd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63517422-45a0-4e78-8505-eca054068ee9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 L/kg to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf320619-c53b-49a7-97b5-cd0c075a9f75 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2716dac-8b23-4e06-bc3e-4dd76b7c813e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48330a8e-be08-4d38-b8b1-d30fbd5a35de (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6ca5cc9-4e5e-40cf-a36e-227aa4cb55c6 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa80b9f4-8a5d-3e14-e053-2a95a90a8aab (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47e484c2-f59e-4a71-bb97-c90f128ac345 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0d5d1cd-c79b-4229-929c-2eb3e4f43298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 L/kg to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abdfb9b9-9402-4761-9347-8eb1c4d86242 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 L/kg to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31f3c720-1597-4d43-9296-33017b90b15f (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:098db8bb-fa9a-4577-b7d9-86caaefc168a (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77e849b8-900b-4f0d-ac5c-1391abcd5721 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9591d4db-2b88-4f0f-b61e-64ba67626e3d (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a422c32-bbdf-4297-84f4-9c438c904b0c (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 L/kg to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac490ebf-24e1-47c4-a932-ad4dcafe7aad (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f1d1da-ce61-45b3-acf4-903cc81d16da (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b685384-5d96-46fa-b93b-e96538a2cfe7 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:955dba5e-c3b7-4a45-8650-e1b4722dbaea (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32b9780f-c46f-4e0f-9641-2cab60600e6e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f93e20b1-97aa-088d-e053-6394a90a25d4 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7a90ccf-9c32-40cc-9008-7e55b3da4dfd (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56fc2167-ceb6-4e3e-8ff7-5e400dfbd533 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eabefa-518b-4030-9b72-01ac8b3deba9 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 L/kg to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78a99bfe-6ebe-4ace-80b0-ee019921435e (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e64036a-ee3e-42e7-9e59-881f88a4e298 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a108fa0-c230-475f-be93-6f864b98a410 (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 - 0.7 L/kg) based on ideal body weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:701fbf9c-e06b-46f4-863b-981acf3021aa (opens source in a new tab)
Theophylline label
Version not recorded · Effective date not recorded
The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3 to 0.7 L/kg) based on ideal body weight.
Projected row 1500
- Medicine slug
- thiotepa
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 12
- Source count
- 8
- Agreement rate
- 0.625
- Recorded readings
1.4 hours
- Numeric value
- 1.4
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8c8bb14-0423-e4a3-8bf0-8a66ce05b1bb (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for TEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:493410f3-0733-4f76-8050-6529d96f2a5b (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for TEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ae8063c-ba28-4da2-a94c-8e1a5f75e4b3 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for TEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b4725eb-95f1-45cc-852f-152beb5f1e2c (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for TEPA.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:add44e98-a042-4e38-b870-beb36693805b (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
In adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for TEPA.
1.7 hours
- Numeric value
- 1.7
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559e353c-2dc0-16ba-e054-00144ff8d46c (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life was 1.7 hours (64%) for thiotepa and 4 hours (29%) for its major active metabolite, N,N',N''-triethylenephosphoramide (TEPA) in pediatric population.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b702dcc9-dd0e-4386-b1e2-f20562fd2ad9 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life was 1.7 hours (64%) for thiotepa and 4 hours (29%) for its major active metabolite, N,N',N''-triethylenephosphoramide (TEPA) in pediatric population.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cd6ae89-c553-4328-9262-4363610a1f19 (opens source in a new tab)
Thiotepa label
Version not recorded · Effective date not recorded
The mean terminal elimination half-life was 1.7 hours (64%) for thiotepa and 4 hours (29%) for its major active metabolite, N,N',N''-triethylenephosphoramide (TEPA) in pediatric population.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1490Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.